Related Experiment Video

Updated: May 27, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Treatment of non-small cell lung cancer]

N Reinmuth1, D Heigener, M Reck

  • 1Internistische Onkologie der Thoraxtumoren, Thoraxklinik am Universitätsklinikum Heidelberg, Amalienstrasse 5, Heidelberg, Germany. niels.reinmuth@thoraxklinik-heidelberg.de

Der Internist
|November 19, 2011
PubMed

Insights

Treatment for non-small cell lung cancer is evolving with new targeted therapies and maintenance strategies. Molecular markers are crucial for personalizing treatment by identifying patient subgroups likely to respond.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Non-small cell lung cancer (NSCLC) treatment landscape is rapidly evolving.
  • Increasing complexity due to new therapeutic agents and strategies.

Purpose:

  • To review the current state of non-small cell lung cancer treatment.
  • Highlight advancements in cytotoxic agents and molecularly targeted drugs.
  • Discuss emerging therapeutic indications like maintenance therapy.

Summary:

  • Recent advancements include novel cytotoxic agents and molecularly targeted drugs for NSCLC.
  • Molecular markers are key to identifying patient subgroups for personalized therapy.
  • Future treatment will increasingly rely on stratifying patients by molecular, histological, or clinical markers.

Impact:

  • Personalized medicine approaches are transforming NSCLC patient care.
  • Improved patient outcomes are expected through tailored treatment strategies.
  • This review provides a comprehensive overview for clinicians and researchers in the field.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...